News

As a result, NPS will receive a milestone payment plus royalties from Kirin Pharma, a wholly-owned subsidiary of Kirin Holdings, which will market the drug in Japan. Kirin

Loss of gastrointestinal neuronal nitric oxide synthase (nNOS) activity is one of the major putative mechanisms for the development of diabetic complications involving the gut, including gastroparesis and

This approval now allows Ethex Corporation, KV’s wholly-owned generic/non-branded subsidiary, to offer a full line of all strengths of this product. Ethex Corporation has commenced the launch of

Furthermore, Epix has completed enrollment of its Phase IIa clinical trial of PRX-03140 in Alzheimer’s disease and reaffirmed that it is on track to announce the findings of

The Phase III program consisted of two studies that compared the safety and efficacy of difluprednate 0.05% to placebo, dosed two (BID) or four (QID) times daily beginning

The agreement grants to MedImmune non-exclusive license rights to develop, manufacture and market antibodies based on Potelligent technology for an undisclosed number of targets. In return, BioWa receives

The partnership matches Novogen’s focus on the identification, preparation, analysis and production of compounds with a leading global beauty company. According to Novogen, a number of its compounds

Additionally, Claritin tablets and Claritin Reditab tablets have been approved for these uses in patients over the age of seven. In Japan, Schering-Plough co-markets the Claritin line of

The orally administered drug, MKC-1, increased survival of tumor-bearing animals in this model. An examination of tumors following five days of oral treatment revealed inhibition of the Akt-mTOR